{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T04:14:07Z","timestamp":1728533647759},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00120-024-02417-0","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T17:52:39Z","timestamp":1724435559000},"page":"977-984","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Therapieans\u00e4tze beim nicht-muskelinvasiven Urothelkarzinom der Harnblase\u00a0\u2013 Ist der Organerhalt auch nach BCG (Bacillus Calmette-Gu\u00e9rin) m\u00f6glich?","New therapeutic approaches for non-muscle invasive bladder cancer\u2014is organ preservation also possible after BCG (Bacillus Calmette Gu\u00e9rin)?"],"prefix":"10.1007","volume":"63","author":[{"given":"Thorsten H.","family":"Ecke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Gakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"issue":"4","key":"2417_CR1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester\u00a0RJ, Rodr\u00edguez\u00a0O, Hern\u00e1ndez\u00a0V et\u00a0al (2021) European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol 79(4):480\u2013488","journal-title":"Eur Urol"},{"issue":"9","key":"2417_CR2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00120-016-0195-1","volume":"55","author":"M Retz","year":"2016","unstructured":"Retz\u00a0M, Gschwend\u00a0JE, Maisch\u00a0P (2016) Short version of the German S3 guideline for bladder cancer. Urologe\u00a0A 55(9):1173\u20131187","journal-title":"Urologe A"},{"issue":"2","key":"2417_CR3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.juro.2010.03.134","volume":"184","author":"DC Chade","year":"2010","unstructured":"Chade\u00a0DC, Shariat\u00a0SF, Adamy\u00a0A et\u00a0al (2010) Clinical outcome of primary versus secondary bladder carcinoma in situ. J\u00a0Urol 184(2):464\u2013469","journal-title":"J Urol"},{"issue":"5","key":"2417_CR4","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","volume":"61","author":"RE Hautmann","year":"2012","unstructured":"Hautmann\u00a0RE, de Petriconi\u00a0RC, Pfeiffer\u00a0C et\u00a0al (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61(5):1039\u20131047","journal-title":"Eur Urol"},{"issue":"3","key":"2417_CR5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester\u00a0RJ, van der Meijden\u00a0AP, Oosterlinck\u00a0W et\u00a0al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a\u00a0combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013465 (discussion 475\u2013467)","journal-title":"Eur Urol"},{"issue":"3","key":"2417_CR6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","volume":"58","author":"BW van Rhijn","year":"2010","unstructured":"van Rhijn\u00a0BW, Zuiverloon\u00a0TC, Vis\u00a0AN et\u00a0al (2010) Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 58(3):433\u2013441","journal-title":"Eur Urol"},{"issue":"3","key":"2417_CR7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","volume":"60","author":"J Fernandez-Gomez","year":"2011","unstructured":"Fernandez-Gomez\u00a0J, Madero\u00a0R, Solsona\u00a0E et\u00a0al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables. Eur Urol 60(3):423\u2013430","journal-title":"Eur Urol"},{"issue":"1","key":"2417_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-018-0105-y","volume":"16","author":"B Jordan","year":"2019","unstructured":"Jordan\u00a0B, Meeks\u00a0JJ (2019) T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol 16(1):23\u201334","journal-title":"Nat Rev Urol"},{"issue":"3","key":"2417_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/PAP.0000000000000152","volume":"24","author":"GP Paner","year":"2017","unstructured":"Paner\u00a0GP et\u00a0al (2017) Challenges in pathologic staging of bladder cancer: poposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances.  Adv Anat Pathol 24(3):113\u2013127. https:\/\/doi.org\/10.1097\/PAP.0000000000000152. (PMID 28398951)","journal-title":"Adv Anat Pathol"},{"issue":"6","key":"2417_CR10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.purol.2010.02.002","volume":"20","author":"B Faivre d\u2019Arcier","year":"2010","unstructured":"Faivre d\u2019Arcier\u00a0B, Celhay\u00a0O, Safsaf\u00a0A et\u00a0al (2010) T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a\/T1b). A\u00a0multicenter study by the French Urological Association (CCAFU). Prog Urol 20(6):440\u2013449","journal-title":"Prog Urol"},{"issue":"4","key":"2417_CR11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.urolonc.2007.05.002","volume":"25","author":"MS Soloway","year":"2007","unstructured":"Soloway\u00a0MS, Lee\u00a0CT, Steinberg\u00a0GD et\u00a0al (2007) Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder. Urol Oncol 25(4):338\u2013340","journal-title":"Urol Oncol"},{"issue":"6","key":"2417_CR12","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.juro.2009.08.083","volume":"182","author":"KS Cho","year":"2009","unstructured":"Cho\u00a0KS, Seo\u00a0HK, Joung\u00a0JY et\u00a0al (2009) Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J\u00a0Urol 182(6):2625\u20132630","journal-title":"J Urol"},{"issue":"5","key":"2417_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0022-5347(17)55150-2","volume":"125","author":"A Morales","year":"1981","unstructured":"Morales\u00a0A, Ottenhof\u00a0P, Emerson\u00a0L (1981) Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J\u00a0Urol 125(5):649\u2013651","journal-title":"J Urol"},{"issue":"1","key":"2417_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(17)52736-6","volume":"128","author":"SA Brosman","year":"1982","unstructured":"Brosman\u00a0SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J\u00a0Urol 128(1):27\u201330","journal-title":"J Urol"},{"issue":"3","key":"2417_CR15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-5347(17)38865-1","volume":"142","author":"MF Sarosdy","year":"1989","unstructured":"Sarosdy\u00a0MF, Lamm\u00a0DL (1989) Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J\u00a0Urol 142(3):719\u2013722","journal-title":"J Urol"},{"issue":"2","key":"2417_CR16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000475138","volume":"27","author":"Y Aso","year":"1995","unstructured":"Aso\u00a0Y, Akaza\u00a0H, Kotake\u00a0T et\u00a0al (1995) Preventive effect of a\u00a0Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a\u00a0double-blind trial. The BLP Study Group. Eur Urol 27(2):104\u2013109","journal-title":"Eur Urol"},{"issue":"3","key":"2417_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","volume":"88","author":"MD Shelley","year":"2001","unstructured":"Shelley\u00a0MD, Kynaston\u00a0H, Court\u00a0J et\u00a0al (2001) A\u00a0systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88(3):209\u2013216","journal-title":"BJU Int"},{"issue":"1","key":"2417_CR18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle\u00a0A, Jocham\u00a0D, Bock\u00a0PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin\u00a0C for superficial bladder cancer: a\u00a0formal meta-analysis of comparative studies on recurrence and toxicity. J\u00a0Urol 169(1):90\u201395","journal-title":"J Urol"},{"issue":"4","key":"2417_CR19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","volume":"93","author":"MD Shelley","year":"2004","unstructured":"Shelley\u00a0MD, Wilt\u00a0TJ, Court\u00a0J et\u00a0al (2004) Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin\u00a0C in reducing tumour recurrence in high-risk superficial bladder cancer: a\u00a0meta-analysis of randomized trials. BJU Int 93(4):485\u2013490","journal-title":"BJU Int"},{"issue":"5","key":"2417_CR20","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester\u00a0RJ, Van der\u00a0MA, Lamm\u00a0DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a\u00a0meta-analysis of the published results of randomized clinical trials. J\u00a0Urol 168(5):1964\u20131970","journal-title":"J Urol"},{"issue":"4","key":"2417_CR21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","volume":"63","author":"A B\u00f6hle","year":"2004","unstructured":"B\u00f6hle\u00a0A, Bock\u00a0PR (2004) Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin\u00a0C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4):682\u2013686 (discussion 686\u2013687)","journal-title":"Urology"},{"issue":"1","key":"2417_CR22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","volume":"174","author":"RJ Sylvester","year":"2005","unstructured":"Sylvester\u00a0RJ, van der Meijden\u00a0AP, Witjes\u00a0JA et\u00a0al (2005) Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a\u00a0meta-analysis of the published results of randomized clinical trials. J\u00a0Urol 174(1):86\u201391 (discussion 91\u201382)","journal-title":"J Urol"},{"issue":"2","key":"2417_CR23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m\u00a0PU, Sylvester\u00a0RJ, Crawford\u00a0DE et\u00a0al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin\u00a0C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"issue":"4","key":"2417_CR24","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm\u00a0DL, Blumenstein\u00a0BA, Crissman\u00a0JD et\u00a0al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a\u00a0randomized Southwest Oncology Group Study. J\u00a0Urol 163(4):1124\u20131129","journal-title":"J Urol"},{"issue":"4","key":"2417_CR25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","volume":"44","author":"RJ Sylvester","year":"2003","unstructured":"Sylvester\u00a0RJ, van der Meijden\u00a0AP, Oosterlinck\u00a0W et\u00a0al (2003) The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a\u00a0European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase\u00a0III Trial. Eur Urol 44(4):423\u2013428","journal-title":"Eur Urol"},{"issue":"1","key":"2417_CR26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk\u00a0M, Burger\u00a0M, Capoun\u00a0O et\u00a0al (2022) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 81(1):75\u201394","journal-title":"Eur Urol"},{"issue":"5","key":"2417_CR27","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","volume":"169","author":"HW Herr","year":"2003","unstructured":"Herr\u00a0HW, Dalbagni\u00a0G (2003) Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J\u00a0Urol 169(5):1706\u20131708","journal-title":"J Urol"},{"issue":"1","key":"2417_CR28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","volume":"57","author":"GS Kulkarni","year":"2010","unstructured":"Kulkarni\u00a0GS, Hakenberg\u00a0OW, Gschwend\u00a0JE et\u00a0al (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57(1):60\u201370","journal-title":"Eur Urol"},{"issue":"1","key":"2417_CR29","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2021.03.024","volume":"40","author":"RL Steinberg","year":"2022","unstructured":"Steinberg\u00a0RL, Packiam\u00a0VT, Thomas\u00a0LJ et\u00a0al (2022) Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a\u00a0single induction course of BCG. Urol Oncol 40(1):9.e1\u20139.e7","journal-title":"Urol Oncol"},{"issue":"4","key":"2417_CR30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","volume":"3","author":"N Milbar","year":"2017","unstructured":"Milbar\u00a0N, Kates\u00a0M, Chappidi\u00a0MR et\u00a0al (2017) Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer. Bladder Cancer 3(4):293\u2013303","journal-title":"Bladder Cancer"},{"issue":"7","key":"2417_CR31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar\u00a0AV, Kamat\u00a0AM, Kulkarni\u00a0GS et\u00a0al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase\u00a02\u00a0study. Lancet Oncol 22(7):919\u2013930","journal-title":"Lancet Oncol"},{"issue":"1","key":"2417_CR32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian\u00a0SA, Alemozaffar\u00a0M, Konety\u00a0BR et\u00a0al (2021) Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a\u00a0single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22(1):107\u2013117","journal-title":"Lancet Oncol"},{"key":"2417_CR33","doi-asserted-by":"crossref","unstructured":"Lotan Y, Agarwal P, Black P et\u00a0al (2024) Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials. Urol Oncol","DOI":"10.1016\/j.urolonc.2024.01.019"},{"issue":"1","key":"2417_CR34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bju.14525","volume":"123","author":"J Breyer","year":"2019","unstructured":"Breyer\u00a0J, Wirtz\u00a0RM, Erben\u00a0P et\u00a0al (2019) FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. BJU Int 123(1):187\u2013196","journal-title":"BJU Int"},{"issue":"9","key":"2417_CR35","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00432-018-2694-5","volume":"144","author":"S Rinaldetti","year":"2018","unstructured":"Rinaldetti\u00a0S, Wirtz\u00a0R, Worst\u00a0TS et\u00a0al (2018) FOXM1 predicts disease progression in non-muscle invasive bladder cancer. J\u00a0Cancer Res Clin Oncol 144(9):1701\u20131709","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2417_CR36","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","volume":"18","author":"M Racioppi","year":"2018","unstructured":"Racioppi\u00a0M, Di Gianfrancesco\u00a0L, Ragonese\u00a0M et\u00a0al (2018) ElectroMotive drug administration (EMDA) of Mitomycin\u00a0C as first-line salvage therapy in high risk \u201eBCG failure\u201c non muscle invasive bladder cancer: 3\u00a0years follow-up outcomes. Bmc Cancer 18(1):1224","journal-title":"Bmc Cancer"},{"issue":"10","key":"2417_CR37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam\u00a0VT, Lamm\u00a0DL, Barocas\u00a0DA et\u00a0al (2018) An open label, single-arm, phase\u00a0II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Urol Oncol 36(10):440\u2013447","journal-title":"Urol Oncol"},{"issue":"3","key":"2417_CR38","first-page":"287","volume":"73","author":"F Chiancone","year":"2020","unstructured":"Chiancone\u00a0F, Fabiano\u00a0M, Fedelini\u00a0M et\u00a0al (2020) Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin\u00a0C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure. Cent european J Urol 73(3):287\u2013294","journal-title":"Cent european J Urol"},{"issue":"2","key":"2417_CR39","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.clgc.2020.11.002","volume":"19","author":"L Di Gianfrancesco","year":"2021","unstructured":"Di Gianfrancesco\u00a0L, Ragonese\u00a0M, Palermo\u00a0G et\u00a0al (2021) Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer 19(2):e100\u2013e119","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"2417_CR40","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi\u00a0A, Roumigui\u00e9\u00a0M, Kamat\u00a0AM et\u00a0al (2024) Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a\u00a0single-arm, multicentre, phase\u00a02\u00a0trial. Lancet Oncol 25(6):720\u2013730","journal-title":"Lancet Oncol"},{"issue":"6","key":"2417_CR41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","volume":"84","author":"PC Black","year":"2023","unstructured":"Black\u00a0PC, Tangen\u00a0CM, Singh\u00a0P et\u00a0al (2023) Phase\u00a02 Trial of Atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol 84(6):536\u2013544","journal-title":"Eur Urol"},{"issue":"1","key":"2417_CR42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","volume":"35","author":"JWF Catto","year":"2024","unstructured":"Catto\u00a0JWF, Tran\u00a0B, Roupr\u00eat\u00a0M et\u00a0al (2024) Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann Oncol 35(1):98\u2013106","journal-title":"Ann Oncol"},{"key":"2417_CR43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2024.01.013","volume":"62","author":"PVV","year":"2024","unstructured":"PVV, van der Heijden\u00a0AG, Cutie\u00a0CJ et\u00a0al (2024) The Safety, Tolerability, and Preliminary Efficacy of a\u00a0Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A\u00a0Phase\u00a01b Study. Eur Urol Open Sci 62:8\u201315","journal-title":"Eur Urol Open Sci"},{"key":"2417_CR44","doi-asserted-by":"crossref","unstructured":"Jaromin M, Konecki T, Kutwin P (2024) Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. Cancers 16(7)","DOI":"10.3390\/cancers16071366"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02417-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T05:02:42Z","timestamp":1728450162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02417-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2417"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02417-0","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"22 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.H.\u00a0Ecke und G.\u00a0Gakis geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}